Portopulmonary hypertension

Jason M Golbin; Michael J Krowka

doi:10.1016/j.ccm.2006.11.004

Portopulmonary hypertension

Clin Chest Med. 2007 Mar;28(1):203-18, ix. doi: 10.1016/j.ccm.2006.11.004.

Authors

Jason M Golbin¹, Michael J Krowka

Affiliation

¹ Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.

PMID: 17338936
DOI: 10.1016/j.ccm.2006.11.004

Abstract

As a result of the success of orthotopic liver transplantation, there has been increasing interest in the diagnosis and therapeutic options for the pulmonary vascular complications of hepatic disease. These pulmonary vascular complications range from the hepatopulmonary syndrome, which is characterized by intrapulmonary vascular dilatations, to portopulmonary hypertension (POPH), which is characterized by an elevated pulmonary vascular resistance as a consequence of obstruction to pulmonary arterial blood flow. This review concentrates on POPH.

Publication types

Review

MeSH terms

Antihypertensive Agents / therapeutic use
Comorbidity
Electrocardiography
Epoprostenol / therapeutic use
Hepatopulmonary Syndrome / diagnosis
Hepatopulmonary Syndrome / physiopathology
Humans
Hypertension, Portal / epidemiology*
Hypertension, Portal / physiopathology
Hypertension, Pulmonary / diagnosis
Hypertension, Pulmonary / epidemiology*
Hypertension, Pulmonary / physiopathology
Liver Transplantation
Patient Selection
Prevalence
Pulmonary Artery / diagnostic imaging
Radiography

Substances

Antihypertensive Agents
Epoprostenol